Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2010 December;62(4) > Minerva Urologica e Nefrologica 2010 December;62(4):377-86

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

REVIEWS  


Minerva Urologica e Nefrologica 2010 December;62(4):377-86

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Bladder cancer: a review of clinical management and prognostic factors

Patel T., Pitman M., Mckiernan J. M.

Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA


PDF  


Bladder cancer is a heterogeneous disease that offers a unique challenge for the patient and the physician as treatment paradigms are continually evolving. There are multiple factors that can influence how each individual is treated, including lymphovascular invasion, micropapillary histology, and p53 nuclear accumulation which have demonstrated a worse prognosis in patients with bladder cancer. They can influence the use of neoadjuvant and adjuvant chemotherapy, which in itself can affect the timing of extirpative surgery. This review will focus on the contemporary management and treatment of bladder cancer focusing on areas of clinical decision making.

top of page

Publication History

Cite this article as

Corresponding author e-mail

tp2200@columbia.edu